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Introduction: Brucein A has been known to have antiplasmodial activity. Some new compounds were
synthesized to increase their antiplasmodial activity, i.e 3-benzoyl brucein A, 3-dimethyl sulphate bruceine
A, 3-choro benzoyl brucein A, and 3-chloro acetyl bruceine A. However, their antiplasmodial activity have
not studied yet.
Objectives: To know the in vitro antiplasmodial activity of 3-benzoyl brucein A, 3-dimethyl sulphate
bruceine A, 3-choro benzoyl brucein A, and 3-chloro acetyl bruceine A.
Methods: Antiplasmodial activity was conducted by incubating FCR-3 strain of P. falciparum with 3-
benzoyl brucein A, 3-dimethyl sulphate bruceine A, 3-choro benzoyl brucein A, and 3-chloro acetyl
bruceine A in various concentrations for 72 hours. Parasitemia after incubation period of each
compound was calculated by making a thin smear stained with 5% Giemsa.
Results: Semisynthetic compounds of bruceine A have antiplasmodial activity in vitro with IC50 value
were 2.648 ± 1.30 ng/mL for 3-benzoyl bruceine A, 1.098 ± 0.510 ng/mL for 3-dimethyl sulphate
bruceine A, 50.246 ± 0.207 ng/mL for 3-chloro benzoyl bruceine A and 67.951 ± 11.517 ng/mL for 3-
chloro acetyl brucein A. The IC50 value of Bruceine A as the lead compound was 3.87 ± 2.530 ng/mL
Conclusion: The 3-dimethyl sulphate bruceine A showed the highest antiplasmodial activity among
4 semisynthetic compounds of Bruceine A.
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INTISARI
Pendahuluan: Brucein A dikenal memiliki aktivitas antiplasmodium yang dibuktikan pada uji
antiplasmodium in vitro . Beberapa senyawa baru turunannya telah disintesis untuk meningkatkan
aktivitasnya yaitu 3-benzoil brucein A, 3-dimetil sulfat bruceine A, 3-kloro benzoil brucein A dan 3-
kloro asetil bruceine A, namun belum dibuktikan potensinya sebagai antiplasmodium.
Tujuan: Menguji aktivitas antiplasmodium in vitro senyawa 3-benzoil brucein A, 3-dimetil sulfate
bruceine A, 3-kloro benzoil brucein A dan 3-kloro asetil bruceine A.
Metode:Uji aktivitas antiplasmodium in vitro dengan menggunakan P. falciparum FCR-3 untuk senyawa
3-benzoil brucein A, 3-dimetil sulfat bruceine A, 3-kloro benzoil brucein A dan 3-kloro asetil bruceine
A pada berbagai peringkat konsentrasi dengan masa inkubasi 72 jam. Parastemia dihitung dari sediaan
apus tipis yang di cat dengan Giemsa 5%.
Hasil: Aktivitas antiplasmodium in vitro senyawa semi sintetik brucein A didapatkan nilai IC50 sebesar
2,648 ± 1,30 ng/mL untuk 3-benzoil bruceine A, 1,098 ± 0510 ng/mL untuk 3-dimetil sulfat bruceine
A, 50,246 ± 0,207 ng/mL untuk 3-kloro benzoil bruceine A dan 67,951 ± 11,517 ng/mL untuk 3-kloro
asetil brucein A. Nilai IC50 Brucein A sebagai senyawa penuntun adalah 3,87 ± 2,530 ng/mL.
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Simpulan: Senyawa 3-dimetil sulfat bruceine A mempunyai aktivitas antiplasmodium in vitro terbaik
diantara keempat senyawa semi sintetik Brucein A
Kata kunci: bruceine A, senyawa semi sintetik, Plasmodium falciparum, aktivitas antiplasmodium in
vitro.
INTRODUCTION
Malaria is one of serious infectious disease in
the world. Drug resistance in malaria parasite is
one of big obstacle on malaria eradication which
cause therapeutic failure moreover death1.
Chloroquine, one of well known antimalaria,
with good therapeutic effect, low cost, low side
effect and has been widely used was reported
to be resistant now. That condition urges the
development of new antimalaria agent. One
strategy in developing new antimalaria agent is by
synthesized new compound from lead compound
which already known to have antiplasmodial
activity. Lead compound are chosen based on
chemical structure which has similarity with
another compound or analogue compound that
has already known having great antiplasmodial
activity2.
Bruceantin compound, brusatol; bruceine A;
bruceine B; dan bruceine C are analogue compound
of cuasinoid group which have antiplasmodial
activity against P. falciparum in vitro . Bruceantin
have lowest IC50 (0.0008 ìg/mL) consecutive with
brusatol, bruceine C, bruceine A and bruceine B.
All of those IC50 were lower than chloroquine
0.210 ìg/mL3,4. Bruceantin compound also have
antiplasmodial activity in vivo against
Plasmodium berghei3.
Another research showed that bruceantine
and brusatol as bruceine A analogue has been
modified its chemical structure for antimalaria,
antimicrobia, and also anticancer5. Based on
research, bruceine A isolated from Brucea
javanica, L., Merr. as a lead compound in antimalaria
development. Chemical structure modification of
bruceine A was conducted by substitute benzyl
chloride pharmacophor, dimethyl sulphate, chloro
benzoic chloride, and chloro acetyl chloride on its
structure and become semi synthetic compound
as consecutively 3-benzoic bruceine A, 3-dimethyl
sulphate bruceine A, 3-chloro benzoic bruceine A,
and 3- chloro acetyl bruceine A6. The substituent
addition was due to enhance its interaction to
Plasmodium with high specificity and low toxicity
against the host7. All the modified compound of
bruceine A (3-benzoic bruceine A, 3-dimethyl
sulphate bruceine A, 3-chloro benzoic bruceine
A, and 3- chloro acetyl bruceine A) never tested
on its antiplasmodial activity assay.
MATERIALS AND METHODS
Antiplasmodial activity in vitro assay of
bruceine A and its semisyntetic compound
a. Plasmodium falciparum culture
P. falciparum culture was performed using
Trager & Jensen method9,10. Malaria culture
medium (MCM) was composed of 10.43g RPMI
1640 powder, 6g HEPES, 2g NaHCO3, 25mg
gentamycin in 1 liter of sterilized aquadest.
Medium was sterilized using micro filter 0.22ìm
pH ± 7.2 and stored at 40C. O blood erythrocytes
were used as parasite medium to grow.
Erythrocytes were washed 3 times to eliminate
anticoagulant, serum, and leucocytes. Packed
erythrocytes were then stored at 4 oC for 14 days.
P. falciparum strain FCR-3 was thawed from
liquid nitrogen storage by adding NaCl 12% after
3 minute warmth. Ten mL of NaCl 1.6% was added
for every 1mL Plasmodium suspension followed
by centrifugation to separate the supernatant.
Ten mL of 0.2% dextrose in 0.9% NaCl was added
followed by centrifugation to get the
Plasmodium pellet.
Complete MCM (cMCM) was made by adding
10 mL malaria culture medium into culture flask,
mix with 10% O blood human serum. Thawed
Plasmodium was poured into a culture flask that
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containing cMCM and 50 ìL of normal erythrocyte.
Culture flask were kept in the candle jar. As
nitrogen source, candle was lit and the jar was
then closed when the candle off. Candle jar was
kept inside CO2 incubator (37
0C) and medium
was replaced at every 24 hours.
b. Antiplasmodial activity assay
For this assay, synchronized ring stadium
was used10.Plasmodium with 2% parasitemia, 3%
haematocrit was used for brucein A in vitro assay.
Bruceine A compound; 3-benzoil bruceine A, 3-
dimethyl sulphate bruceine A, 3-chloro benzoyl
bruceine A, and 3-chloro acetyl bruceine A were
dissolved in DMSO solution and diluted with
RPMI. Samples concentration were 1, 2, 4, 8, 16
ng/mL for bruceine A, 3-benzoil bruceine A, 3-
dimethyl sulphate bruceine A. For 3- chloro
acetyl bruceine A, the sample concentration
were 20, 40, 80, 160, 320 ng/mL. RPMI was used
for negative control. Chloroquin was used to
explore its sensitivity against P. falciparum with
concentration 4, 8, 12,16 and 20 Kg/mL. Sample
solutions (100µL) with various concentration were
put into 96 well micro plate with added 100µL of
infected erythrocytes. Each concentration was
replicated 3 times. Each sample was tested duplex
except for 3-chloro acetyl bruceine A (once).
Micro plate was kept into candle jar and
incubated at 37oC for 72 hours. At the end of
incubation time, thin smear of P. falciparum was
made for each well, 5% Giemsa stained and
examined under microscope. Parasitaemia and
percentage of parasite growth inhibition were
calculated for each well.
c. Statistical analysis
Probit analysis was utilized to determine
antiplasmodial activity which expressed as IC50.
RESULTS AND DISCUSSIONS
Antiplasmodial activity in vitro assay of brucein
A and its derivates
Bruceine A and its derivates 3-benzoil bruceine
A, 3-dimethyl sulphate bruceine A, 3-chloro
benzoyl bruceine A, and 3-chloro acetyl bruceine
A were tested its antiplasmodial activity in vitro
against chloroquine-sensitive P. falciparum. P.
falciparum growth was evaluated using thin smear
and examined under microscope. Chloroquine was
used a positive control and DMSO was used a
solvent control. Results of antiplasmodial activity
of some compounds and chloroquine were listed
in Table 1.
Antiplasmodial activity was expressed as
IC50. The IC50 for 3-benzoil bruceine A was 2.648
± 1.30 ng/mL; 3-dimethyl sulphate bruceine A
was 1.098 ± 0.510 ng/mL; 3-chloro benzoyl
bruceine A was 50.246 ± 0.207 ng/mL; 3-chloro
acetyl bruceine A was 67.951 ± 11.517 ng/mL; and
bruceine A as lead compound was 3.87 ± 2.530
ng/mL. The IC50 of chloroquine as positive
control was 4.808 ± 0.096 ng/mL.
Antiplasmodial activity in vitro assay is an early
exploration stage for compound which will develop
as antimalaria. Bruceine A and its derivates was
examined its antiplasmodial activity against P.
falciparum chloroquine sensitive. Bruceine A was
a lead compound that possessed antiplasmodial
activity and also its derivates. Bruceine A was
modified by substitution of pharmacophor group
(benzoic chloride, dimethyl sulphate, chloro
benzoic chloride, and chloro acetyl chloride) into
its derivates 3-benzoil bruceine A, 3-dimethyl
sulphate bruceine A, 3-chloro benzoyl bruceine A,
and 3- chloro acetyl bruceine A. Those new
compounds potential for further antimalarial drug
development. Bruceine A, 3-benzoil bruceine A,
and 3-dimethyl sulphate bruceine A possessed
lower IC50 level than chloroquine and both
derivates also possessed lower IC50 level than the
lead compound, bruceine A.
Based on Egan10 requirements, a compound
stated having poor activity or has no effect if the
IC50 level 20 times higher than chloroquine’s
IC50
10. The IC50 of chloroquine was 4.08 ± 0.096
ng/mL and twenty times of it was 96.16 ng/mL.
The IC50 of bruceine A and all the derivates were
lower than chloroquine based on Egan criteria10.
Hence those compounds are potential to be
further investigated.
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Table 1. Antiplasmodial activity of Bruceine A and it derivates against P. falciparum FCR-3
strain in in vitro assay
CONCLUSION
This research showed that all of Bruceine A
derivates have potential antiplasmodial activity in
vitro. Further study is needed for in vitro
cytotoxicity of bruceine A semisynthetic compound
on normal cells.
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